Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Irinotecan Liposomes +5-FU/LV or Capecitabine in Patients at High Risk of Recurrence After Resection of Resectable Biliary Tract Carcinoma: A Prospective Phase II Study

NCT06699459 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT06699459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06699459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Irinotecan Liposomes +5-FU/LV or Capecitabine in Patients at High Risk of Recurrence After Resection of Resectable Biliary Tract Carcinoma: A Prospective Phase II Study
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 14, 2024
Completion date
November 15, 2026
Enrollment
76 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract carcinoma